AdjuTec Pharma leads €2.2M Eurostars project to combat deadly lung infections

– Our lead product APC301 has shown excellent preclinical efficacy in a group of bacteria called Enterobacterales that are the main cause of cUTI infections.

These patients are the most common, with the highest mortality worldwide and represent a highly attractive commercial opportunity, says Jethro Holter and Bjørn Klem.